AnaptysBio, Inc. (ANAB) News
Filter ANAB News Items
ANAB News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
ANAB News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest ANAB News From Around the Web
Below are the latest news stories about ANAPTYSBIO INC that investors may wish to consider to help them evaluate ANAB as an investment opportunity.
Big Biotech Fund Loads Up on a Stock That Surged in 2024, and a LoserEcoR1 bought more shares of Zymeworks and AnaptysBio, and remains the largest investor in both companies. |
Are Medical Stocks Lagging United Therapeutics (UTHR) This Year?Here is how United Therapeutics (UTHR) and AnaptysBio, Inc. (ANAB) have performed compared to their sector so far this year. |
Anaptys to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceSAN DIEGO, Jan. 07, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer of Anaptys, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 14, 2025 at 4:30pm PT / 7:30pm ET. A live webcast of the presentation will be available on the investor section of the Anaptys website at http://ir.anaptysbio |
AnaptysBio Stock Down as Eczema Study Fails to Meet GoalsPhase IIb study on ANAB's ANB032 for atopic dermatitis fails to meet goals. The company decides to discontinue any further investment in the candidate. |
AnaptysBio’s atopic dermatitis trial of BTLA agonist misses endpointsDespite the setback, the therapy was well tolerated with no safety concerns observed. |
AnaptysBio Discontinues Investment In Eczema Candidate After Disappointing DataOn Wednesday, AnaptysBio, Inc. (NASDAQ:ANAB) announced that investigational ANB032, a BTLA agonist, did not meet the primary and secondary endpoints in any of the doses studied in the ARISE-AD trial as a monotherapy for moderate-to-severe atopic dermatitis (AD) or eczema. “While ANB032 was safe and well tolerated, we’re disappointed by these efficacy results in AD and will discontinue further investment in this asset. Moving forward, our resources and capital will be focused on the rest of our e |
Top Midday DeclinersQ32 Bio (QTTB) said late Tuesday its phase 2a clinical trial in atopic dermatitis failed to meet the |
Is Siga Technologies (SIGA) Stock Outpacing Its Medical Peers This Year?Here is how Siga Technologies Inc. (SIGA) and AnaptysBio, Inc. (ANAB) have performed compared to their sector so far this year. |
Anaptys Announces Phase 2b Trial of ANB032, a BTLA Agonist, Did Not Meet Primary or Secondary Endpoints in Atopic DermatitisANB032 was well tolerated across all doses with no safety signals observedAD trial and all further investment in ANB032 will be discontinuedAnticipate top-line Phase 2b data in rheumatoid arthritis in February 2025 for rosnilimab, a PD-1+ T cell depleter and agonistFunded beyond additional clinical data catalysts including Phase 2 data in ulcerative colitis for rosnilimab and Phase 1b data for ANB033 and ANB101Year-end 2024 cash of approximately $415 million and extending cash runway guidance th |
Are Medical Stocks Lagging AnaptysBio (ANAB) This Year?Here is how AnaptysBio, Inc. (ANAB) and Castle Biosciences, Inc. (CSTL) have performed compared to their sector so far this year. |